Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.
This interventional pilot study will assess the use of low dose naltrexone (LDN) and NAD+ for
the treatment of patients with post-COVID-19 syndrome (long-COVID-19).
Patients with a positive test for SARS-CoV-2 1-4 months before enrollment will be included.
Subjects should have self diagnosed post-COVID19 syndrome and experiencing persistent fatigue
since positive test. Patients will be screened using the fatigue survey and cases with a
moderate to severe score will be included.
Patients will receive LDN and NAD+ treatment for 12 weeks. In this study, fatigue and quality
of life will be assessed using validated surveys. Surveys will be conducted at baseline (at
the time of enrollments, before treatment), and at 2, 4, 8, and 12 weeks. The improvement of
scores from baseline levels will be assessed.
Drug: Naltrexone
Naltrexone at 4.5 mg/day
Other Name: Low dose Naltrexone (LDN)
Dietary Supplement: NAD+
NAD+ will be applied using iontophoresis patches. The patches will be provided by ready-made NAD+ solutions (400 mg) to be applied to the positive electrode of the patch and saline to the negative electrode. The patch is powered by a self-contained battery, producing an electric current to facilitate NAD+ absorption through the skin into the blood. Patches are worn for 4-6 hours once a week.
Other Name: Nicotinamide adenine dinucleotide
Inclusion Criteria:
- Any ethnicity
- Adequate cognitive function to be able to give informed consent
- Technologically competent to complete web forms and perform video calls with the PI
- Positive PCR test (polymerase chain reaction) result for SARS-CoV-2 (severe acute
respiratory syndrome coronavirus 2) 1-4 months before enrollment
- A fatigue score above 9 in the Chalder Fatigue scale upon enrollment
- Willing to fill out regular questionnaires
- Willing to use LDN and NAD patches
Exclusion Criteria:
- Clinically significant kidney, heart, Hepatic impairment as determined by clinical
judgement
- Taking opioid analgesics, or undergoing treatment for opioid addiction
- Opioid dependence or withdrawal syndrome
- Known sensitivity to naltrexone
- Suspected or confirmed pregnancy or breastfeeding
- Known issues with using iontophoresis patches
- Active cancers
- Enrolled in another trial
- Current users of LDN or NAD+
AgelessRx
Ann Arbor, Michigan, United States